Type Subsidiary Industry Pharmaceuticals Number of employees 1,152 Parent organization Endo International plc | Traded as Formerly NYSE: PRX Net income $12,600,000 USD (2005) Founded 1978 | |
 | ||
Products >110 Generic and branded specialty pharmaceuticals Revenue $433,200,000 USD (2005) Headquarters Woodcliff Lake, New Jersey, United States CEO Paul Campanelli (Sep 2012–) Subsidiaries Kali Laboratories, Inc, Par Pharma Group Ltd | ||
Welcome to par pharmaceutical inc
Par Pharmaceutical develops, manufactures and markets generic and branded specialty pharmaceuticals. Par was founded in 1978 and initially traded on the New York Stock Exchange in 1987. Par is currently the fifth largest generic pharmaceutical company in the United States.
Contents
- Welcome to par pharmaceutical inc
- Par pharmaceutical companies celebrates 25th anniversary of listing and rings the nyse closing bell
- Facilities
- IntelliPharmaCeutics
- References
In 2012, Par Pharmaceutical agreed to be acquired by the private equity firm TPG Capital. In 2015, TPG sold Par to Endo International.
Par pharmaceutical companies celebrates 25th anniversary of listing and rings the nyse closing bell
Facilities
The company is based in the United States, with corporate headquarters in Woodcliff Lake, New Jersey and additional facilities for research, manufacturing and distribution in Irvine, California, Suffern, New York, Huntsville, Alabama, Chestnut Ridge, New York and Chennai,India.
IntelliPharmaCeutics
In 2007 Par Pharmaceutical signed a drug development collaboration with pharmaceutical research company IntelliPharmaCeutics Inc,. Under the arrangement, IntelliPharmaCeutics will apply its proprietary technology to the formulation and development of four generic drug products (ANDA's) which are bioequivalent to existing branded drugs with commercial sales in the United States. The terms of the deal provide that Par will be responsible for certain costs of development, and that IntelliPharmaCeutics will receive milestone payments, incentive payments and success-based payments along with a share of the profits of commercialization. Par will be responsible for the distribution of the drugs in the United States.